Last Update 17.09.2018
The International Agency for Research on Cancer just released a new list of classification. It is strongly recommended to consult the complete Monographs on these agents, the publication date and the list of studies considered.
| Group 1 | Carcinogenic to humans | 120 agents |
| Group 2A | Probably carcinogenic to humans | 82 |
| Group 2B | Possibly carcinogenic to humans | 302 |
| Group 3 | Not classifiable as to its carcinogenicity to humans | 501 |
| Group 4 | Probably not carcinogenic to humans | 1 |
|
For definitions of these groups, please see the Preamble. |
||
| It is strongly recommended to consult the complete Monographs on these agents, the publication date, and the list of studies considered. Significant new information might support a different classification. | ||
| For agents that have not been classified, no determination of non-carcinogenicity or overall safety should be inferred. | ||
Visual:
The Preamble to the IARC Monographs describes the objective and scope of the programme, the scientific principles and procedures used in developing a Monograph, the types of evidence considered and the scientific criteria that guide the evaluations. The Preamble should be consulted when reading a Monograph or list of evaluations.
- List of classifications, Volumes 1-122
- List of classifications by cancer site
- Preventable Exposures Associated With Human Cancers (Cogliano et al., 2011)
IARC 2018
Collegati
ID 24177 | 27.06.2025
Regolamento delegato (UE) 2025/718 della Commissione, del 14 aprile 2025,...
Regolamento delegato (UE) 2019/157 della Commissione del 6 novembre 2018 che modifica l'allegato II del regolamento delegato (UE) n. 1062/2014 relativo al programma d...
2015 marks the 50th anniversary of pharmaceutical legislation in the EU, which began with Directive 65/65 in 1965 in the wake of the Thalidomide disaster.
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024
